Compare · MENS vs NVO
MENS vs NVO
Side-by-side comparison of Jyong Biotech Ltd. (MENS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MENS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $172.11B, about 1293.6x MENS ($133.0M).
- NVO has hit the wire 9 times in the past 4 weeks while MENS has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for MENS).
- Company
- Jyong Biotech Ltd.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $133.0M
- $172.11B
- 1M return
- -
- -0.41%
- 1Y return
- -
- -18.26%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 0
- 9
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MENS
- Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California
- Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates
- Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow
- Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
- Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
- Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
- Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
- SEC Form 20-F filed by Jyong Biotech Ltd.
- SEC Form NT 20-F filed by Jyong Biotech Ltd.
- SEC Form 3 filed by new insider Zhang Wei (Vivi)
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S